16,515 Shares in Standard BioTools Inc. (NASDAQ:LAB) Purchased by Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. bought a new stake in Standard BioTools Inc. (NASDAQ:LAB) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 16,515 shares of the company’s stock, valued at approximately $29,000. Standard BioTools comprises about 0.1% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 11th biggest holding.

Other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Standard BioTools in the fourth quarter valued at approximately $70,000. American Century Companies Inc. grew its position in Standard BioTools by 19.4% in the fourth quarter. American Century Companies Inc. now owns 218,889 shares of the company’s stock valued at $383,000 after purchasing an additional 35,599 shares in the last quarter. GM Advisory Group LLC acquired a new stake in Standard BioTools in the 4th quarter valued at $350,000. Cibc World Markets Corp bought a new stake in Standard BioTools during the 4th quarter worth about $48,000. Finally, Royce & Associates LP boosted its stake in shares of Standard BioTools by 136.8% during the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company’s stock worth $2,547,000 after buying an additional 840,951 shares during the last quarter. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Trading Up 2.6 %

NASDAQ:LAB opened at $1.19 on Thursday. The stock has a market capitalization of $450.99 million, a PE ratio of -1.68 and a beta of 1.62. Standard BioTools Inc. has a 1-year low of $0.99 and a 1-year high of $3.04. The firm has a fifty day simple moving average of $1.35 and a 200 day simple moving average of $1.69.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded Standard BioTools from an “overweight” rating to a “sector weight” rating in a research report on Thursday, February 27th.

Insider Buying and Selling at Standard BioTools

In other Standard BioTools news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the stock in a transaction on Friday, February 28th. The shares were purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the transaction, the director now directly owns 58,846,780 shares in the company, valued at $62,377,586.80. This represents a 8.92 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 53.10% of the company’s stock.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.